MAPT and Alzheimer disease: As analyzed from western blotting analysis, quantified brain Aβ, phosphorylated Tau, and NFTs expression levels of 3× Tg-AD mice were significantly greater than those of non-AD mice (Figures 7(b)(B), 8(b)(B), and 9(b)(B), P < 0.01), while quantified brain Aβ, phosphorylated Tau, and NFTs expression levels of B401-treated 3× Tg-AD mice were significantly decreased compared to those of 3× Tg-AD mice with sham treatment (Figures 7(b)(B), 8(b)(B), and 9(b)(B), P < 0.01).